This website is intended for healthcare professionals only

Trending Topic

16 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Hypertension is the leading modifiable risk factor for global cardiovascular disease, responsible for an estimated 10.8 million deaths and more than 200 million disability-adjusted life years annually.1 Despite the availability of effective pharmacological and lifestyle interventions, prevalence continues to rise, particularly in low- and middle-income countries (LMICs), where over three-quarters of all cases now occur.2 The condition’s […]

Marked prolongation of QRS duration after initiation of dronedarone therapy

Conrad Genz, Hans D. Esperer, Alexander Schmeisser, Ruediger C. Braun-Dullaeus, Samir M. Said
< 1 min
Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Download as PDF
Published Online: Aug 10th 2018 Heart International 2014;9(1):33-35 DOI: https://doi.org/10.5301/HEART.2014.12491
Select a Section…
1

Abstract

Overview

Dronedarone is a relatively new antiarrhythmic drug and is held to be less proarrhythmic than comparable compounds,
although its proarrhythmia potential in humans has not been sufficiently evaluated. We describe a so far
unreported dronedarone effect, namely a significant alteration of both the morphology and the duration of the
QRS complex on the electro cardiogram in a 41-year old patient with symptomatic paroxysmal atrial fibrillation.

Keywords

Adverse drug events, Antiarrhythmic drugs, Atrial fibrillation, Dronedarone.

2

Article Information

Correspondence

Samir M. Said, Otto-von-Guericke University University Hospital, Centre of Internal Medicine Division of Cardiology Leipziger Str. 44 39120 Magdeburg, Germany samir.said@med.ovgu.de

3

Further Resources

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Download as PDF
Close Popup